While ‘data exclusivity’ clauses will not feature in the India-European Union free trade agreement (FTA), the threat posed by the impending deal to the world’s supply of cheap generic drugs is far from over. India’s commerce and industry minister Anand Sharma assured Michel Sidibe, chief of the United Nations joint programme on HIV and AIDS (UNAIDS) at a meeting this week that India would reject attempts by pharmaceutical giants to include...

Moves by developed nations such as the United States to tighten intellectual property laws are threatening to limit production and distribution of generic drugs, which experts say have been and will remain key in the prevention and treatment of HIV/AIDS and currently account for 80 percent of HIV/AIDS treatment. These efforts are taking shape in two spheres. The first is in discussions on the outcome document that member states are expected...

To increase transparency, India’s patent regulator will soon make public details about patented drugs which include whether domestic demand for these medicines is met at a reasonable price. Patent holders in the country are required to submit once every year the so-called working details which include the quantity and value of a product that is sold, manufacturing base, quantity of production or imports, and a statement on whether public requirement has...

United States has placed India, Pakistan, China and nine other countries on the top 'priority watch list' with regard to violations of intellectual property rights (IPR). America's trading partners on the Priority Watch List present the most significant concerns regarding insufficient IPR protection or enforcement, or otherwise limited market access for persons relying on intellectual property protection. Twelve countries-India, Pakistan, China, Russia, Algeria, Argentina, Canada, Chile, Indonesia, Israel, Thailand and Venezuela are...

The government may approve acquisitions of local drugmakers by global firms on a case-by-case basis on certain conditions to ensure availability of medicines at affordable prices, despite calls for restrictions on such deals in the wake of a spate of takeovers in the last three years. Multinationals may have to move buyout proposals through the Foreign Investment Promotion Board (FIPB), allowing the government to understand the firm's rationale for buying a...